| 74 75 | RET Moline J, Eng C. Multiple endocrine neoplasia type 2. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. 1999 Sep 27 [updated 2015 Jun 25]. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565-612. SDHA, SDHB, and SDHC Kirmani S, Young WF. Hereditary paraganglioma-pheochromocytoma syndromes. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. 2008 May 21 [updated 2014 Nov 6]. Lefebvre M, Foulkes WD. Pheochromocytoma and paraganglioma syndromes: genetics and management update. Curr Oncol. 2014;21(1):e8-e17. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942. STK11 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) for Genetic/ Familial High Risk Assessment: Breast and Ovarian Version V.1.2018. © National Comprehensive Cancer Network, Inc 2017. All rights reserved. Accessed March 1, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) for Genetic/ Familial High Risk Assessment: Colorectal Version V.3.2017. © National Comprehensive Cancer Network, Inc 2016. All rights reserved. Accessed March 1, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12(10):3209-3215. McGarrity TJ, Amos CI, Frazier ML, et al. Peutz-Jeghers syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. 2001 Feb 23 [updated 2016 Jul 14]. van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME. High cancer risk in Peutz- Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010 105:1258-1264. TP53 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) for Genetic/ Familial High Risk Assessment: Breast and Ovarian Version V.1.2018. © National Comprehensive Cancer Network, Inc 2017. All rights reserved. Accessed March 1, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. Schneider K, Zelley K, Nichols KE, et al. Li-Fraumeni syndrome. In: Pagon RA, Adam MP, Amemiya A, et al., eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. 1999 Jan 19 [updated 2013 Apr 11]. Wu CC, Shete S, Amos CI, et al. Joint effects of germ-line P53 mutation and sex on cancer risk in Li-Fraumeni syndrome. Cancer Res. 2006;66:8287-8292. VHL Frantzen C, Links TP, Giles RH. von Hippel-Lindau disease. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. 2000 May 17 [updated 2015 Aug 6]. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19(6):617-623. Maher ER, Iselius L, Yates JR, et al. Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991;28:443-447. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res. 2011;13(1):R20. doi:10.1186/bcr2832. Li J, Meeks H, Feng BJ, et al. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. J Med Genet. 2016;53(1):34-42. doi:10.1136/jmedgenet-2015-103452. Minion LE, Dolinsky JS, Chase DM, Dunlop CL, Chao EC, Monk BJ. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. Gynecol Oncol. 2015;137(1):86-92. doi:10.1016/j.ygyno.2015.01.537. Mosor M, Ziółkowska-Suchanek I, Roznowski K, et al. RAD50 gene mutations are not likely a risk factor for breast cancer in Poland. Breast Cancer Res Treat. 2010;123(2):607-609. doi:10.1007/s10549-010-0992-y. Rajkumar T, Meenakumari B, Mani S, Sridevi V, Sundersingh S. Targeted resequencing of 30 genes improves the detection of deleterious mutations in South Indian women with breast and/or ovarian cancers. Asian Pac J Cancer Prev. 2015;16(13):5211-5217. Rebbeck TR, Mitra N, Domchek SM, et al; and Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE). Modification of BRCA1-associated breast and ovarian cancer risk by BRCA1 interacting genes. Cancer Res. 2011;71(17):5792-5805. doi:10.1158/0008-5472.CAN-11-0773. Rouleau E, Jesson B, Briaux A, et al. Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition. Breast Cancer Res Treat. 2012;133(3):1179-1190. doi:10.1007/ s10549-012-2009-5. Tommiska J, Seal S, Renwick A, et al. Evaluation of RAD50 in familial breast cancer predisposition. Int J Cancer. 2006;118(11):2911-2916. Uhrhammer N, Delort L, Bignon YJ. Rad50 c.687delT does not contribute significantly to familial breast cancer in a French population. Cancer Epidemiol Biomarkers Prev. 2009;18(2):684-685. doi:10.1158/1055-9965.EPI-08-0971. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032-18037. doi:10.1073/ pnas.1115052108. Waltes R, Kalb R, Gatei M, et al. Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder. Am J Hum Genet. 2009; 84(5): 605-616. doi:10.1016/j.ajhg.2009.04.0101999. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) for Genetic/ Familial High Risk Assessment: Breast and Ovarian Version V.1.2018. © National Comprehensive Cancer Network, Inc 2017. All rights reserved. Accessed March 1, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. RAD51C and RAD51D Loveday C, Turnbull C, Ramsay E, et al; and Breast Cancer Susceptibility Collaboration (UK). Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 2011;43(9):879-882. doi:10.1038/ng.893. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42(5):410-414. doi:10.1038/ng.569. Song H, Dicks E, Ramus SJ, et al. contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol. 2015;33(26):2901-2907. doi:10.1200/JCO.2015.61.2408. Loveday C, Turnbull C, Ruark E, et al; and Breast Cancer Susceptibility Collaboration (UK). Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet. 2012;44(5):475-476; author reply 476. doi:10.1038/ng.2224. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) for Genetic/ Familial High Risk Assessment: Breast and Ovarian Version V.1.2018. © National Comprehensive Cancer Network, Inc 2017. All rights reserved. Accessed March 1, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org.